-

Ono Shares Replay Information for 44th Annual J.P. Morgan Healthcare Conference Presentation

OSAKA, Japan--(BUSINESS WIRE)--Ono Pharmaceutical Co., Ltd. (TSE:4528), today announced that Toichi Takino, President and COO, presented at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026, at 11:15 a.m. PST / 2:15 p.m. EST.

An audio recording of the event is available here and accessible until February 15, 2026.

About Ono Pharmaceutical Co., Ltd.
Ono Pharmaceutical Co., Ltd. delivers innovative therapies for patients worldwide. Upholding its philosophy of “Dedicated to the Fight against Disease and Pain,” Ono targets areas with unmet medical needs including oncology, immunology, and neurology, and fosters partnerships with academic and biotech organizations to accelerate drug discovery. Through its affiliate, Deciphera Pharmaceuticals, Ono is accelerating clinical development and commercial operations in the US and Europe to drive global business expansion and further its commitment to patient care. For more information, please visit the company's website at https://www.ono-pharma.com/en.

Contacts

Ono Pharmaceutical Co., Ltd.
Corporate Communications
public_relations@ono-pharma.com

Industry:

Ono Pharmaceutical Co., Ltd.

TOKYO:4528
Release Versions
English

Contacts

Ono Pharmaceutical Co., Ltd.
Corporate Communications
public_relations@ono-pharma.com

More News From Ono Pharmaceutical Co., Ltd.

Ono Pharma Receives Orphan Medicinal Product Designation for Sapablursen from European Commission and Plans to Present Trial-in-Progress Poster at ASH 2026

OSAKA, Japan--(BUSINESS WIRE)--Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”) today announced that the European Commission has granted Orphan Medicinal Product Designation to sapablursen (ONO-0530) in polycythemia vera (PV). Sapablursen has previously received Fast Track Designation in January 2024, Orphan Drug Designation in August 2024, and Breakthrough Therapy Designation in May 2025 from the U.S. Food and Drug Administration (FDA). In Japa...

Ono Pharma Announces Results From Five Phase 2 Clinical Studies of ONO-1110, an Endocannabinoid Modulator

OSAKA, Japan--(BUSINESS WIRE)--Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”) today announced that ONO-1110, an endocannabinoid modulator, demonstrated efficacy signals in Phase 2 clinical studies in postherpetic neuralgia (PHN), fibromyalgia (FM), and Hunner-type interstitial cystitis (HIC). Additional Phase 2 clinical studies of ONO-1110 were conducted in major depressive disorder (MDD) and social anxiety disorder (SAD). Although the ONO-111...

Ono Pharma Enters into a Drug Discovery Partnership with Aitia in Neurological Diseases

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”) today announced that it has entered into a drug discovery partnership agreement with Aitia, Inc. (Headquarters: Cambridge, Massachusetts, USA; CEO: Colin Hill; “Aitia”). Under the terms of the agreement, Aitia will utilize its REFS™ technology to build Gemini Digital Twins (GDTs) of neurological diseases and identify new therapeutic targets and bio...
Back to Newsroom